nach oben

Medical Oncology

Erschienen in:

01.03.2022 | Original Paper

Bioinformatics analysis of recurrent deletion regions in neuroblastoma

verfasst von: Hasan Onur Caglar

Erschienen in: Medical Oncology | Ausgabe 3/2022

Einloggen, um Zugang zu erhalten

Abstract

Neuroblastoma (NB) is the most common extra-cranial solid tumor in childhood. Very few genes in recurrent deletion regions have been identified as tumor suppressors for NB, and interactions among proteins encoded by genes in these regions have been overlooked. This study aims to identify possible tumor suppressor genes located within regions commonly deleted in NB tumors and to show possible interaction network of proteins encoded by genes in these regions by bioinformatics analysis. The genes localized in the recurrent deletion regions were identified using the Ensembl BioMart web-tool. GSE1824 microarray dataset was analyzed to determine downregulated differently expressed genes (dDEGs) selected from deletion regions using Orange Canvas software. The DAVID v6.8 tool and Reactome database were used to perform gene ontology and pathway enrichment analysis, respectively. The protein–protein interaction (PPI) network and sub-module analysis were conducted by STRING database and Cytoscape plugin MCODE software, respectively. Copy number variation status and mutations of hub genes were examined in TARGET neuroblastoma dataset using UCSC Xena platform. Biological processes of genes were specific to chromosomes. The 219 genes selected from these regions were found to be downregulated. A PPI network was constructed for dDEGs. Copy number losses and mutations were observed for hub genes. Hub genes identified in the current study may act as tumor suppressors in NB tumorigenesis. Disruption of protein–protein interaction network consisting of proteins encoded by genes on various recurrent deletion regions may give rise to NB by interrupting gene regulatory network orchestrating neural crest formation.

Nur mit Berechtigung zugänglich

Zafar A, Wang W, Liu G, Wang X, Xian W, McKeon F, et al. Molecular targeting therapies for neuroblastoma: progress and challenges. Med Res Rev. 2021;41(2):961–1021.PubMedCrossRef

Bilke S, Chen QR, Wei JS, Khan J. Whole chromosome alterations predict survival in high-risk neuroblastoma without MYCN amplification. Clin Cancer Res. 2008;14(17):5540–7.PubMedPubMedCentralCrossRef

Caren H, Kryh H, Nethander M, Sjoberg RM, Trager C, Nilsson S, et al. High-risk neuroblastoma tumors with 11q-deletion display a poor prognostic, chromosome instability phenotype with later onset. Proc Natl Acad Sci USA. 2010;107(9):4323–8.PubMedPubMedCentralCrossRef

Nakagawara A, Li Y, Izumi H, Muramori K, Inada H, Nishi M. Neuroblastoma. Jpn J Clin Oncol. 2018;48(3):214–41.PubMedCrossRef

Bown N. Neuroblastoma tumour genetics: clinical and biological aspects. J Clin Pathol. 2001;54(12):897–910.PubMedPubMedCentralCrossRef

Matthay KK, Maris JM, Schleiermacher G, Nakagawara A, Mackall CL, Diller L, et al. Neuroblastoma. Nat Rev Dis Primers. 2016;2:16078.PubMedCrossRef

Sauka-Spengler T, Bronner-Fraser M. A gene regulatory network orchestrates neural crest formation. Nat Rev Mol Cell Biol. 2008;9(7):557–68.PubMedCrossRef

Ji Y, Hao H, Reynolds K, McMahon M, Zhou CJ. Wnt signaling in neural crest ontogenesis and oncogenesis. Cells. 2019;8(10):1173.PubMedCentralCrossRef

Tribulo C, Aybar MJ, Nguyen VH, Mullins MC, Mayor R. Regulation of Msx genes by a Bmp gradient is essential for neural crest specification. Development. 2003;130(26):6441–52.PubMedCrossRef

10.

Monsoro-Burq AH, Wang E, Harland R. Msx1 and Pax3 cooperate to mediate FGF8 and WNT signals during Xenopus neural crest induction. Dev Cell. 2005;8(2):167–78.PubMedCrossRef

11.

Basch ML, Bronner-Fraser M, Garcia-Castro MI. Specification of the neural crest occurs during gastrulation and requires Pax7. Nature. 2006;441(7090):218–22.PubMedCrossRef

12.

Thompson PM, Seifried BA, Kyemba SK, Jensen SJ, Guo C, Maris JM, et al. Loss of heterozygosity for chromosome 14q in neuroblastoma. Med Pediatr Oncol. 2001;36(1):28–31.PubMedCrossRef

13.

Suzuki T, Yokota J, Mugishima H, Okabe I, Ookuni M, Sugimura T, et al. Frequent loss of heterozygosity on chromosome 14q in neuroblastoma. Cancer Res. 1989;49(5):1095–8.PubMed

14.

Brodeur GM, Sekhon G, Goldstein MN. Chromosomal aberrations in human neuroblastomas. Cancer. 1977;40(5):2256–63.PubMedCrossRef

15.

Caron H, van Sluis P, Buschman R, Pereira do Tanque R, Maes P, Beks L, et al. Allelic loss of the short arm of chromosome 4 in neuroblastoma suggests a novel tumour suppressor gene locus. Hum Genet. 1996;97(6):834–7.PubMedCrossRef

16.

Johnsen JI, Dyberg C, Wickstrom M. Neuroblastoma-A neural crest derived embryonal malignancy. Front Mol Neurosci. 2019;12:9.PubMedPubMedCentralCrossRef

17.

Tang H, Sun X, Reinberg D, Ebright RH. Protein-protein interactions in eukaryotic transcription initiation: structure of the preinitiation complex. Proc Natl Acad Sci USA. 1996;93(3):1119–24.PubMedPubMedCentralCrossRef

18.

Lu H, Zhou Q, He J, Jiang Z, Peng C, Tong R, et al. Recent advances in the development of protein-protein interactions modulators: mechanisms and clinical trials. Signal Transduct Target Ther. 2020;5(1):213.PubMedPubMedCentralCrossRef

19.

Kinsella RJ, Kahari A, Haider S, Zamora J, Proctor G, Spudich G, et al. Ensembl BioMarts: a hub for data retrieval across taxonomic space. Database (Oxford). 2011;2011:bar30.CrossRef

20.

da Huang W, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc. 2009;4(1):44–57.CrossRef

21.

Staege MS, Hutter C, Neumann I, Foja S, Hattenhorst UE, Hansen G, et al. DNA microarrays reveal relationship of Ewing family tumors to both endothelial and fetal neural crest-derived cells and define novel targets. Cancer Res. 2004;64(22):8213–21.PubMedCrossRef

22.

Demšar J, Curk T, Erjavec A, Gorup C, Hočevar T, Milutinovič M, et al. Orange: data mining toolbox in Python. J Mach Learn Res. 2013;14:2349–53.

23.

Fabregat A, Sidiropoulos K, Garapati P, Gillespie M, Hausmann K, Haw R, et al. The reactome pathway Knowledgebase. Nucleic Acids Res. 2016;44(D1):D481-487.PubMedCrossRef

24.

Szklarczyk D, Gable AL, Lyon D, Junge A, Wyder S, Huerta-Cepas J, et al. STRING v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. Nucleic Acids Res. 2019;47(D1):D607–13.PubMedCrossRef

25.

Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, Ramage D, et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 2003;13(11):2498–504.PubMedPubMedCentralCrossRef

26.

Bader GD, Hogue CW. An automated method for finding molecular complexes in large protein interaction networks. BMC Bioinformatics. 2003;4:2.PubMedPubMedCentralCrossRef

27.

Kanehisa M, Goto S. KEGG: kyoto encyclopedia of genes and genomes. Nucleic Acids Res. 2000;28(1):27–30.PubMedPubMedCentralCrossRef

28.

Goldman MJ, Craft B, Hastie M, Repecka K, McDade F, Kamath A, et al. Visualizing and interpreting cancer genomics data via the Xena platform. Nat Biotechnol. 2020;38(6):675–8.PubMedPubMedCentralCrossRef

29.

Giwa A, Fatai A, Gamieldien J, Christoffels A, Bendou H. Identification of novel prognostic markers of survival time in high-risk neuroblastoma using gene expression profiles. Oncotarget. 2020;11(46):4293–305.PubMedPubMedCentralCrossRef

30.

Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012;2(5):401–4.PubMedCrossRef

31.

Pugh TJ, Morozova O, Attiyeh EF, Asgharzadeh S, Wei JS, Auclair D, et al. The genetic landscape of high-risk neuroblastoma. Nat Genet. 2013;45(3):279–84.PubMedPubMedCentralCrossRef

32.

Molenaar JJ, Koster J, Zwijnenburg DA, van Sluis P, Valentijn LJ, van der Ploeg I, et al. Sequencing of neuroblastoma identifies chromothripsis and defects in neuritogenesis genes. Nature. 2012;483(7391):589–93.PubMedCrossRef

33.

Peifer M, Hertwig F, Roels F, Dreidax D, Gartlgruber M, Menon R, et al. Telomerase activation by genomic rearrangements in high-risk neuroblastoma. Nature. 2015;526(7575):700–4.PubMedPubMedCentralCrossRef

34.

Ambros PF, Ambros IM, Strehl S, Bauer S, Luegmayr A, Kovar H, et al. Regression and progression in neuroblastoma. Does genetics predict tumour behaviour. Eur J Cancer. 1995;31A(4):510–5.PubMedCrossRef

35.

Janoueix-Lerosey I, Novikov E, Monteiro M, Gruel N, Schleiermacher G, Loriod B, et al. Gene expression profiling of 1p35-36 genes in neuroblastoma. Oncogene. 2004;23(35):5912–22.PubMedCrossRef

36.

Siemers NO, Holloway JL, Chang H, Chasalow SD, Ross-MacDonald PB, Voliva CF, et al. Genome-wide association analysis identifies genetic correlates of immune infiltrates in solid tumors. PLoS ONE. 2017;12(7):e0179726.PubMedPubMedCentralCrossRef

37.

Melaiu O, Chierici M, Lucarini V, Jurman G, Conti LA, De Vito R, et al. Cellular and gene signatures of tumor-infiltrating dendritic cells and natural-killer cells predict prognosis of neuroblastoma. Nat Commun. 2020;11(1):5992.PubMedPubMedCentralCrossRef

38.

Szemes M, Melegh Z, Bellamy J, Greenhough A, Kollareddy M, Catchpoole D, et al. A Wnt-BMP4 signaling axis induces MSX and NOTCH proteins and promotes growth suppression and differentiation in neuroblastoma. Cells. 2020; 9

39.

Szemes M, Greenhough A, Melegh Z, Malik S, Yuksel A, Catchpoole D, et al. Wnt signalling drives context-dependent differentiation or proliferation in neuroblastoma. Neoplasia. 2018;20(4):335–50.PubMedPubMedCentralCrossRef

40.

Macaluso M, Paggi MG, Giordano A. Genetic and epigenetic alterations as hallmarks of the intricate road to cancer. Oncogene. 2003;22(42):6472–8.PubMedCrossRef

41.

Marshall B, Isidro G, Martins AG, Boavida MG. Loss of heterozygosity at chromosome 9p21 in primary neuroblastomas: evidence for two deleted regions. Cancer Genet Cytogenet. 1997;96(2):134–9.PubMedCrossRef

42.

Villamon E, Berbegall AP, Piqueras M, Tadeo I, Castel V, Djos A, et al. Genetic instability and intratumoral heterogeneity in neuroblastoma with MYCN amplification plus 11q deletion. PLoS ONE. 2013;8(1):e53740.PubMedPubMedCentralCrossRef

43.

Takita J, Hayashi Y, Kohno T, Yamaguchi N, Hanada R, Yamamoto K, et al. Deletion map of chromosome 9 and p16 (CDKN2A) gene alterations in neuroblastoma. Cancer Res. 1997;57(5):907–12.PubMed

44.

Rabbani MA, Ribaudo M, Guo JT, Barik S. Identification of interferon-stimulated gene proteins that inhibit human parainfluenza virus type 3. J Virol. 2016;90(24):11145–56.PubMedPubMedCentralCrossRef

45.

Chen B, Jin S, Bai B, Li Z, Ni C, Liu Y. Knockdown of interferon-stimulated gene 15 affects the sensitivity of hepatocellular carcinoma cells to norcantharidin. Exp Ther Med. 2019;18(5):3751–8.PubMedPubMedCentral

46.

Huang WC, Tung SL, Chen YL, Chen PM, Chu PY. IFI44L is a novel tumor suppressor in human hepatocellular carcinoma affecting cancer stemness, metastasis, and drug resistance via regulating met/Src signaling pathway. BMC Cancer. 2018;18(1):609.PubMedPubMedCentralCrossRef

47.

Britzen-Laurent N, Lipnik K, Ocker M, Naschberger E, Schellerer VS, Croner RS, et al. GBP-1 acts as a tumor suppressor in colorectal cancer cells. Carcinogenesis. 2013;34(1):153–62.PubMedCrossRef

48.

Xu XX, Wan H, Nie L, Shao T, Xiang LX, Shao JZ. RIG-I: a multifunctional protein beyond a pattern recognition receptor. Protein Cell. 2018;9(3):246–53.PubMedCrossRef

49.

Potenza N, Papa U, Russo A. Differential expression of Dicer and Argonaute genes during the differentiation of human neuroblastoma cells. Cell Biol Int. 2009;33(7):734–8.PubMedCrossRef

50.

Brodeur GM, Green AA, Hayes FA, Williams KJ, Williams DL, Tsiatis AA. Cytogenetic features of human neuroblastomas and cell lines. Cancer Res. 1981;41:4678–86.PubMed

51.

Gilbert F. Solid tumors of children: chromosome abnormalities and the development of cancer. J Cell Physiol Suppl. 1984;3:165–70.PubMedCrossRef

52.

Gilbert F, Feder M, Balaban G, Brangman D, Lurie DK, Podolsky R, et al. Human neuroblastomas and abnormalities of chromosomes 1 and 17. Cancer Res. 1984;44(11):5444–9.PubMed

53.

Hafez M, El-Meadday M, Sheir M, Al-Tonbarry Y, Nada N, El-Desoky I. Chromosomal analysis of neuroblastoma. Br J Cancer. 1985;51(2):237–43.PubMedPubMedCentralCrossRef

54.

Fong CT, Dracopoli NC, White PS, Merrill PT, Griffith RC, Housman DE, et al. Loss of heterozygosity for the short arm of chromosome 1 in human neuroblastomas: correlation with N-myc amplification. Proc Natl Acad Sci USA. 1989;86(10):3753–7.PubMedPubMedCentralCrossRef

55.

Martinsson T, Weith A, Cziepluch C, Schwab M. Chromosome 1 deletions in human neuroblastomas: generation and fine mapping of microclones from the distal 1p region. Genes Chromosom Cancer. 1989;1(1):67–78.PubMedCrossRef

56.

Mora J, Cheung NK, Kushner BH, LaQuaglia MP, Kramer K, Fazzari M, et al. Clinical categories of neuroblastoma are associated with different patterns of loss of heterozygosity on chromosome arm 1p. J Mol Diagn. 2000;2(1):37–46.PubMedPubMedCentralCrossRef

57.

Fong CT, White PS, Peterson K, Sapienza C, Cavenee WK, Kern SE, et al. Loss of heterozygosity for chromosomes 1 or 14 defines subsets of advanced neuroblastomas. Cancer Res. 1992;52(7):1780–5.PubMed

58.

Takayama H, Suzuki T, Mugishima H, Fujisawa T, Ookuni M, Schwab M, et al. Deletion mapping of chromosomes 14q and 1p in human neuroblastoma. Oncogene. 1992;7(6):1185–9.PubMed

59.

Srivatsan ES, Ying KL, Seeger RC. Deletion of chromosome 11 and of 14q sequences in neuroblastoma. Genes Chromosomes Cancer. 1993;7(1):32–7.PubMedCrossRef

60.

Srivatsan ES, Murali V, Seeger RC. Loss of heterozygosity for alleles on chromosomes 11q and 14q in neuroblastoma. Prog Clin Biol Res. 1991;366:91–8.PubMed

61.

Guo C, White PS, Hogarty MD, Brodeur GM, Gerbing R, Stram DO, et al. Deletion of 11q23 is a frequent event in the evolution of MYCN single-copy high-risk neuroblastomas. Med Pediatr Oncol. 2000;35(6):544–6.PubMedCrossRef

62.

Guo C, White PS, Weiss MJ, Hogarty MD, Thompson PM, Stram DO, et al. Allelic deletion at 11q23 is common in MYCN single copy neuroblastomas. Oncogene. 1999;18(35):4948–57.PubMedCrossRef

63.

Maris JM, Guo C, White PS, Hogarty MD, Thompson PM, Stram DO, et al. Allelic deletion at chromosome bands 11q14-23 is common in neuroblastoma. Med Pediatr Oncol. 2001;36(1):24–7.PubMedCrossRef

64.

Krona C, Caren H, Sjoberg RM, Sandstedt B, Laureys G, Kogner P, et al. Analysis of neuroblastoma tumour progression; loss of PHOX2B on 4p13 and 17q gain are early events in neuroblastoma tumourigenesis. Int J Oncol. 2008;32(3):575–83.PubMed

65.

Perri P, Longo L, Cusano R, McConville CM, Rees SA, Devoto M, et al. Weak linkage at 4p16 to predisposition for human neuroblastoma. Oncogene. 2002;21(54):8356–60.PubMedCrossRef

66.

Mora J, Alaminos M, de Torres C, Illei P, Qin J, Cheung NK, et al. Comprehensive analysis of the 9p21 region in neuroblastoma suggests a role for genes mapping to 9p21-23 in the biology of favourable stage 4 tumours. Br J Cancer. 2004;91(6):1112–8.PubMedPubMedCentralCrossRef

67.

Giordani L, Iolascon A, Servedio V, Mazzocco K, Longo L, Tonini GP. Two regions of deletion in 9p22- p24 in neuroblastoma are frequently observed in favorable tumors. Cancer Genet Cytogenet. 2002;135(1):42–7.PubMedCrossRef

68.

Furuta S, Ohira M, Machida T, Hamano S, Nakagawara A. Analysis of loss of heterozygosity at 16p12-p13 (familial neuroblastoma locus) in 470 neuroblastomas including both sporadic and mass screening tumors. Med Pediatr Oncol. 2000;35(6):531–3.PubMedCrossRef

69.

Depuydt P, Boeva C, Hocking TD, Cannoodt R, Ambros IM, Ambros PF, et al. Genomic amplifications and distal 6q loss: novel markers for poor survival in high-risk neuroblastoma patients. J Natl Cancer Inst. 2018;110(10):1084–93.PubMedPubMedCentralCrossRef

70.

Hoebeeck J, Michels E, Menten B, Van Roy N, Eggert A, Schramm A, et al. High resolution tiling-path BAC array deletion mapping suggests commonly involved 3p21-p22 tumor suppressor genes in neuroblastoma and more frequent tumors. Int J Cancer. 2007;120(3):533–8.PubMedCrossRef

71.

Spitz R, Hero B, Ernestus K, Berthold F. Deletions in chromosome arms 3p and 11q are new prognostic markers in localized and 4s neuroblastoma. Clin Cancer Res. 2003;9(1):52–8.PubMed

72.

Spitz R, Hero B, Ernestus K, Berthold F. FISH analyses for alterations in chromosomes 1, 2, 3, and 11 define high-risk groups in neuroblastoma. Med Pediatr Oncol. 2003;41(1):30–5.PubMedCrossRef

Titel: Bioinformatics analysis of recurrent deletion regions in neuroblastoma
verfasst von: Hasan Onur Caglar
Publikationsdatum: 01.03.2022
Verlag: Springer US
Erschienen in: Medical Oncology / Ausgabe 3/2022
Print ISSN: 1357-0560
Elektronische ISSN: 1559-131X
DOI: https://doi.org/10.1007/s12032-021-01639-y

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Bioinformatics analysis of recurrent deletion regions in neuroblastoma

Abstract

Neu im Fachgebiet Onkologie

Alphablocker schützt vor Miktionsproblemen nach der Biopsie

Antikörper-Wirkstoff-Konjugat hält solide Tumoren in Schach

Mammakarzinom: Senken Statine das krebsbedingte Sterberisiko?

Labor, CT-Anthropometrie zeigen Risiko für Pankreaskrebs

Update Onkologie

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2022

DNA damage induced cellular senescence and it’s PTEN-armed exosomes—the warriors against prostate carcinoma cells

Comparative expression analysis of dasatinib and ponatinib-regulated lncRNAs in chronic myeloid leukemia and their network analysis

The combination therapy of Everolimus and anti-PD-1 improves the antitumor effect by regulating CD8+ T cells in bladder cancer

SOX2 knockdown with siRNA reverses cisplatin resistance in NSCLC by regulating APE1 signaling

Who should be treated with pembrolizumab in addition to standard of care in advanced cervical cancer?

Critical pathways of oral squamous cell carcinoma: molecular biomarker and therapeutic intervention

Neu im Fachgebiet Onkologie

Alphablocker schützt vor Miktionsproblemen nach der Biopsie

Antikörper-Wirkstoff-Konjugat hält solide Tumoren in Schach

Mammakarzinom: Senken Statine das krebsbedingte Sterberisiko?

Labor, CT-Anthropometrie zeigen Risiko für Pankreaskrebs

Update Onkologie